Though the study did not meet statistical significance for Primary Endpoint, significant improvements were seen in a prespecified subgroup with severe hyperphagia. Significant positive changes were also seen in two of three key secondary endpoints. Interim analysis of Ongoing Extension Study (C602) showed further reductions in hyperphagia of 48% after six months of DCCR treatment. Soleno will host a conference call and live webcast today at 5:00 PM EST.
PWSA | USAView posts by PWSA | USA
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
September 9, 2021
Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
July 22, 2021
Soleno Therapeutics Provides Update on DCCR for the Treatment of PWS
July 7, 2021